Molecular Imaging in Drug Discovery and Development

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Noninvasive imaging has played an increasing role in the process of cardiovascular drug development. This review focuses specifically on the use of molecular imaging, which has been increasingly applied to improve and accelerate certain preclinical steps in drug development, including the identification of appropriate therapeutic targets, evaluation of on-target and off-target effects of candidate therapies, assessment of dose response, and the evaluation of drug or biological biodistribution and pharmacodynamics. Unlike the case in cancer medicine, in cardiovascular medicine, molecular imaging has not been used as a primary surrogate clinical end point for drug approval. However, molecular imaging has been applied in early clinical trials, particularly in phase 0 studies, to demonstrate proof-of-concept or to explain variation in treatment effect. Many of these applications where molecular imaging has been used in drug development have involved the retasking of technologies that were originally intended as clinical diagnostics. With greater experience and recognition of the rich information provided by in vivo molecular imaging, it is anticipated that it will increasingly be used to address the enormous time and costs associated with bringing a new drug to clinical launch.

Original languageEnglish (US)
Article numbere005355
JournalCirculation: Cardiovascular Imaging
Volume11
Issue number2
DOIs
StatePublished - Feb 1 2018

Fingerprint

Molecular Imaging
Drug Discovery
Medicine
Pharmaceutical Preparations
Drug Approval
Cardiovascular Agents
Drug Evaluation
Biomarkers
Clinical Trials
Technology
Costs and Cost Analysis
Therapeutics
Neoplasms

Keywords

  • cardiovascular agents
  • drug approval
  • drug discovery
  • molecular imaging
  • molecular medicine

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging
  • Cardiology and Cardiovascular Medicine

Cite this

Molecular Imaging in Drug Discovery and Development. / Lindner, Jonathan; Link, Jeanne.

In: Circulation: Cardiovascular Imaging, Vol. 11, No. 2, e005355, 01.02.2018.

Research output: Contribution to journalArticle

@article{408f7102994548f9b913a934675954a4,
title = "Molecular Imaging in Drug Discovery and Development",
abstract = "Noninvasive imaging has played an increasing role in the process of cardiovascular drug development. This review focuses specifically on the use of molecular imaging, which has been increasingly applied to improve and accelerate certain preclinical steps in drug development, including the identification of appropriate therapeutic targets, evaluation of on-target and off-target effects of candidate therapies, assessment of dose response, and the evaluation of drug or biological biodistribution and pharmacodynamics. Unlike the case in cancer medicine, in cardiovascular medicine, molecular imaging has not been used as a primary surrogate clinical end point for drug approval. However, molecular imaging has been applied in early clinical trials, particularly in phase 0 studies, to demonstrate proof-of-concept or to explain variation in treatment effect. Many of these applications where molecular imaging has been used in drug development have involved the retasking of technologies that were originally intended as clinical diagnostics. With greater experience and recognition of the rich information provided by in vivo molecular imaging, it is anticipated that it will increasingly be used to address the enormous time and costs associated with bringing a new drug to clinical launch.",
keywords = "cardiovascular agents, drug approval, drug discovery, molecular imaging, molecular medicine",
author = "Jonathan Lindner and Jeanne Link",
year = "2018",
month = "2",
day = "1",
doi = "10.1161/CIRCIMAGING.117.005355",
language = "English (US)",
volume = "11",
journal = "Circulation. Cardiovascular imaging",
issn = "1941-9651",
publisher = "Lippincott Williams and Wilkins",
number = "2",

}

TY - JOUR

T1 - Molecular Imaging in Drug Discovery and Development

AU - Lindner, Jonathan

AU - Link, Jeanne

PY - 2018/2/1

Y1 - 2018/2/1

N2 - Noninvasive imaging has played an increasing role in the process of cardiovascular drug development. This review focuses specifically on the use of molecular imaging, which has been increasingly applied to improve and accelerate certain preclinical steps in drug development, including the identification of appropriate therapeutic targets, evaluation of on-target and off-target effects of candidate therapies, assessment of dose response, and the evaluation of drug or biological biodistribution and pharmacodynamics. Unlike the case in cancer medicine, in cardiovascular medicine, molecular imaging has not been used as a primary surrogate clinical end point for drug approval. However, molecular imaging has been applied in early clinical trials, particularly in phase 0 studies, to demonstrate proof-of-concept or to explain variation in treatment effect. Many of these applications where molecular imaging has been used in drug development have involved the retasking of technologies that were originally intended as clinical diagnostics. With greater experience and recognition of the rich information provided by in vivo molecular imaging, it is anticipated that it will increasingly be used to address the enormous time and costs associated with bringing a new drug to clinical launch.

AB - Noninvasive imaging has played an increasing role in the process of cardiovascular drug development. This review focuses specifically on the use of molecular imaging, which has been increasingly applied to improve and accelerate certain preclinical steps in drug development, including the identification of appropriate therapeutic targets, evaluation of on-target and off-target effects of candidate therapies, assessment of dose response, and the evaluation of drug or biological biodistribution and pharmacodynamics. Unlike the case in cancer medicine, in cardiovascular medicine, molecular imaging has not been used as a primary surrogate clinical end point for drug approval. However, molecular imaging has been applied in early clinical trials, particularly in phase 0 studies, to demonstrate proof-of-concept or to explain variation in treatment effect. Many of these applications where molecular imaging has been used in drug development have involved the retasking of technologies that were originally intended as clinical diagnostics. With greater experience and recognition of the rich information provided by in vivo molecular imaging, it is anticipated that it will increasingly be used to address the enormous time and costs associated with bringing a new drug to clinical launch.

KW - cardiovascular agents

KW - drug approval

KW - drug discovery

KW - molecular imaging

KW - molecular medicine

UR - http://www.scopus.com/inward/record.url?scp=85048377715&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85048377715&partnerID=8YFLogxK

U2 - 10.1161/CIRCIMAGING.117.005355

DO - 10.1161/CIRCIMAGING.117.005355

M3 - Article

VL - 11

JO - Circulation. Cardiovascular imaging

JF - Circulation. Cardiovascular imaging

SN - 1941-9651

IS - 2

M1 - e005355

ER -